Compare WETH & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WETH | DARE |
|---|---|---|
| Founded | 1992 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.1M | 21.0M |
| IPO Year | 2020 | 2014 |
| Metric | WETH | DARE |
|---|---|---|
| Price | $1.34 | $1.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 33.3K | ★ 62.7K |
| Earning Date | 11-12-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $42,280,373.00 | $2,807,885.00 |
| Revenue This Year | N/A | $3,843.33 |
| Revenue Next Year | N/A | $8,700.33 |
| P/E Ratio | $2.28 | ★ N/A |
| Revenue Growth | ★ 6.48 | N/A |
| 52 Week Low | $0.76 | $1.27 |
| 52 Week High | $3.68 | $9.19 |
| Indicator | WETH | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 49.53 |
| Support Level | $1.31 | N/A |
| Resistance Level | $1.42 | $1.74 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 47.62 | 72.06 |
Wetouch Technology Inc is a touch panel supplier focused on R&D, production, and sales of touch screen products. It offers touchscreens for a variety of applications, including GPS/car entertainment panels for the automotive industry, industrial human-machine interface, financial and banking terminals, point of sale, lottery and gaming machines, smart home, robots, and charging stations. The company sells touchscreen products both domestically in China and internationally. The company generates the majority of its revenue from the PRC, followed by the Republic of China and Korea.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.